|
|||||
|
|
Phase I study of DMP 840 in pediatric patients with refractory solid tumors |
|
| Authors: | Joyce Thompson Charles B. Pratt Clinton F. Stewart Loraine Avery Laura Bowman William C. Zamboni Alberto Pappo |
| Affiliation: | (1) Departments of Hematology/Oncology Sciences, St. Jude Children's Research Hospital, USA;(2) Departments of Pediatrics, College of Medicine, The University of Tennessee, Memphis, Tennessee, USA;(3) Departments of Pharmaceutical Sciences, St. Jude Children's Research Hospital, USA |
| Abstract: | The bis-naphthalimide DMP 840 has demonstrated high level antitumor activity in a number of preclinical models and has been evaluated in several Phase I studies in adults. We enrolled 10 patients with refractory pediatric solid tumors to this Phase I study of DMP 840 given intravenously by short infusion daily for 5 days. The most frequent and dose-limiting toxicity was myelosuppression. The maximum tolerated dose on this schedule was 8.6 mg/m2 daily for 5 days. One patient had a complete response; there were no measurable tumor responses among the remaining 9 patients. |
| Keywords: | DMP 840 pediatric tumors phase I study |
| 本文献已被 SpringerLink 等数据库收录！ | |